Clinical trial
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and…
NCT00329082 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00329082 |
|---|---|
| Title | Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers |
| Official title | LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | LY2062430, Placebo |
| Enrollment | 25 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 24, 2006 |
| Last update posted | Oct 7, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: